Travere Therapeutics Inc (NASDAQ: TVTX) stock suffered a major decline of -11.8% on 11/8/23. The shares closed at $6.33. The stock has been extremely weak relative to the market over the last nine months and has declined -2.3% during the last week.
Current PriceTarget Research Rating
TVTX's future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Travere Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR's two proprietary measures of a stock's current attractiveness are providing highly consistent signals. Travere Therapeutics has a very low Appreciation Score of 2 and a very low Power Rating of 1, triggering the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.